.Pharmacolibrary.Drugs.ATC.L.L01XX78

Information

name:Navitoclax
ATC code:L01XX78
route:oral
compartments:2
dosage:150mg
volume of distribution:271L
clearance:4.1L/h
other parameters in model implementation

Navitoclax is a small-molecule, orally bioavailable inhibitor of the anti-apoptotic Bcl-2 family of proteins, including Bcl-2, Bcl-xL, and Bcl-w. It is investigated as an anticancer agent due to its ability to induce apoptosis in cancer cells. It is not widely approved for clinical use and is mostly used in clinical trials for hematologic malignancies and some solid tumors.

Pharmacokinetics

Pharmacokinetic parameters reported in adult patients with cancer following oral administration of navitoclax, single-dose and multiple-dose, in phase I clinical trials.

References

  1. Kaefer, A, et al., & Xiong, H (2014). Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer chemotherapy and pharmacology 74(3) 593–602. DOI:10.1007/s00280-014-2530-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25053389

  2. King, AC, et al., & Tang, LA (2017). Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies. The Annals of pharmacotherapy 51(5) 410–416. DOI:10.1177/1060028016685803 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28056525

Revisions


Generated at 2025-08-11T18:21:04Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos